Nexstim First Half 2025 Earnings: Misses Expectations

Nexstim (HEL:NXTMH) First Half 2025 Results

Key Financial Results

• Revenue: €5.37m (up 36% from 1H 2024).
• Net loss: €338.8k (loss narrowed by 64% from 1H 2024).
• €0.05 loss per share (improved from €0.14 loss in 1H 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nexstim Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 24%. Earnings per share (EPS) was also behind analyst expectations.

Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Finland.

Performance of the Finnish Medical Equipment industry.

The company's shares are down 9.1% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Nexstim that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.